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Short Report
Effects of common genetic variants associated with colorectal
cancer risk on survival outcomes after diagnosis: A large
population-based cohort study
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Genome-wide association studies have thus far identified 130 genetic variants linked to colorectal cancer (CRC) risk (r2 < 0.2). Given
their implication in disease causation, and thus plausible biologically effects on cancer-relevant biological pathways, we investigated
whether these variants are associated with CRC prognosis and also whether they might provide predictive value for survival outcome.
We conducted the analysis in a well-characterized population-based study of 5,675 patients after CRC diagnosis in Scotland. None of
the genetic risk variants were associated with either overall survival (OS) or CRC-specific survival. Next, we combined the variants in
a polygenic risk score, but again we observed no association between survival outcome and overall genetic susceptibility to CRC
risk—as defined by common genetic variants (OS: hazard ratio = 1.00, 95% confidence interval = 0.96–1.05). Furthermore, we found
no incremental increase in the discriminative performance when adding these genetic variants to the baseline CRC-survival predictive
model of age, sex and stage at diagnosis. Given that our study is well-powered (>0.88) to detect effects on survival for 74% of the
variants, we conclude that effects of common variants associated with CRC risk which have been identified to date are unlikely to
have clinically relevant effect on survival outcomes for patients diagnosed with CRC.
Introduction
Globally, colorectal cancer (CRC) is the second leading cause of
cancer-related deaths, accounting for 9.2% of all cancer-related
deaths (0.8 million CRC deaths in 2018).1 The strongest known
predictor of CRC outcome is stage, but even within one stage, there
is considerable heterogeneity in survival. Identification of bio-
markers of cancer prognosis can inform clinical management and
treatment of disease. Evidence of the family concordance for CRC-
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specific survival,2 together with some suggestions of improved sur-
vival in cancer patients with a family history compared to patients
without a family history,3 indicates that genetic signature can affect
prognosis of CRCpatients after diagnosis. Indeed, improved survival
for Lynch syndrome patients with germline rare variations in DNA
mismatch repair genes is well documented,4 suggesting that genetic
variants associated with CRC pathogenesis may subsequently affect
tumor progression. However, very few studies with sufficient power
tested roles of common genetic risk variants in CRC prognosis. Pre-
viously published smaller studies examined up to 30 CRC risk
genetic loci and detected no or little evidence of associations with
survival.5–7 Two recent largemeta-analyses of genome-wide associa-
tion studies (GWAS)8,9 have identified more than 70 new genetic
variants associated with CRC risk. In this analysis, we investigated
the association between all previously and newly GWAS-identified
common genetic variants andCRC survival.
Materials and Methods
We included 5,675 CRC cases (detailed patient selection in
Supporting Information Fig. S1) with genome-wide genotyping data
and data on age at diagnosis, sex and American Joint Committee on
Cancer (AJCC) stage information from a population-based case–
control study (Study of Colorectal Cancer in Scotland, SOCCS;
1999-current).10 Ethics approval was obtained from theMultiCentre
Research Ethics committee for Scotland (approval number
MREC/01/0/5) and other committees (presented elsewhere10). A
total of 130 genetic variants identified by previous GWAS studies8,9
were genotyped or imputed (25/130 variants were directly gen-
otyped). For correlated variants (linkage disequilibrium r2 > 0.2), we
selected ones with smaller p values in the association with CRC risk.
Genotyping was conducted using the Illumina HumanHap300,
HumanHap240S and OmniExpressExome BeadChip 8v1 arrays.
Standard quality control measures were applied as described previ-
ously.9,11,12 Untyped variants were imputed using SHAPEIT v213
and IMPUTEv214 softwares based on a merged reference panel
comprising of 1,000 Genomes Project (phase 1, December 2013
release) and UK10K (April 2014 release) samples. We excluded
poorly imputed variants (informationmeasure <0.80) and rare vari-
ants (minor allele frequency [MAF] <0.05%) as presented in the pre-
vious publication.9 Death registration and cause of death was
ascertained from the Scottish Cancer Registry (SCR), and patients
were prospectively followed up until death or July 1, 2017 (censored
date), whichever came first. The survival outcomes included overall
survival (OS) and CRC specific survival (CSS). The criteria of assig-
ning cause of death can be found elsewhere.15 In order to measure
the overall genetic CRC susceptibility, we created polygenic risk
scores (PRS) including all the 130 variants based on the number of
CRC risk alleles carried by each patient. We employed Cox propor-
tional hazards models to investigate effects of individual variant
(additive model) and the PRS on survival outcomes adjusting for
age at diagnosis, gender and AJCC stage. Bonferroni correction for
multiple testing was adopted and p < 0.0005 was considered statisti-
cal significance.We also used the false positive rates (FDR) approach
(p < 0.05 was the significance threshold after correction) as a sensi-
tivity analysis.16 A summary of the 130 included genetic variants is
presented in Supporting Information Table S1. Using the method
provided by Owzar et al.,17 we calculated the power of variants with
variousminor allele frequency (MAF) on a range of effects. Stratified
analyses were also performed by sex, stage and tumor site. To further
explore the potential predictive value of these variants, we applied a
least absolute shrinkage and selection operator (LASSO) regression
model with 10-fold cross-validation in 70% randomly selected
patients (training set) to select predictors.18 Harrell’s concordance
indices (C statistic) were calculated to measure the discriminative
ability of selected predictors in the remaining 30% patients (test set)
and a U-statistic test was adopted to determine the probability that
added genetic variants could increase themodel concordance.19
We also compared hazard ratio (HR) for OS and CSS with the
risk results from a recently published meta-analysis of genome-wide
association studies of CRC risk.9 We excluded ambiguous AT and
CG variants (n = 6, rs10161980, rs2186607, rs2696839, rs2732875,
rs61336918, rs7398375) from the analysis to avoid bias due to
strand differences between studies. For the variants included in the
analysis (n = 124), we aligned alleles and effect estimates between
GWAS on risk and SOCCS survival analysis. We hypothesized that
in case of no effects, the CRC risk variants will cause improvement
or impairment of OS and CSS in equal proportion (62 variants with
effects on risk and survival going in the same direction vs. 62 vari-
ants with effects on risk and survival going in opposite directions).
We further counted all instances of results with similar directions of
effects such a HR and OR above 1 or below 1 and compared it to
the expected distribution using exact binomial test. Proportions of
risk variants associated with worse OS and CSS and corresponding
95% confidence intervals (CIs) were calculated.
All genetic variants were annotated using (i) association with
the cis gene expression in colon transverse tissue (n = 246) from
the Genotype-Tissue Expression (GTEx) database,20 (ii) presence
of known and predicted regulatory elements in RegulomeDB
database21 and (iii) predicted effect on the structure and function
of a protein as implemented in SIFT22 and PolyPhen-2.23
What’s new?
Genetic variants associated with colorectal cancer (CRC) risk potentially also exert effects on disease prognosis, though little is
known about the heritability of CRC survival. In this population-based study, genetic variants of CRC susceptibility were
investigated for their relevance in CRC survival based on analyses of variants identified in genome-wide association studies
(GWASs). Nonsignificant associations were detected between small numbers of genetic variants and overall survival and CRC-
specific survival. Overall, the findings do not support the existence of prognostic effects of common CRC risk variants. Rather,
CRC survival may have distinct genetic determinants, warranting separate investigation by GWAS.
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The data that support the findings of our study are available
upon reasonable request from the corresponding authors.
The data are not publicly available due to privacy or ethical
restrictions.
Results and Discussion
The basic characteristics of included CRC patients are summarized
in Table 1. In total, 1,918 patients (34%) died during follow-up.
With 5,675 CRC cases, our study had 88% power to detect a haz-
ard ratio of 1.20 on OS for 97/130 (74%) variants (MAF > 0.15) at
the significance level of 0.0005 (a power curve for other effects is
shown in Fig. 1). Overall, we observed 14 genetic variants associ-
ated with OS and 10 with CSS at nominal statistical significance
(p < 0.05) with six variants (rs10994860, rs12143541, rs3217810,
rs34405347, rs6065668, rs847208) being associated with both OS
and CSS. However, none of the variants remained statistically sig-
nificant after Bonferroni or FDR correction. The summary results
for variants with nominal significance are presented in Table 2.
Stratified analyses by stage, sex and tumor site did not identify any
statistically significant associations after multiple-testing correc-
tion either (Supporting Information Tables S2–S4). With regard
to overall genetic susceptibility to CRC, no statistically significant
association was observed between the PRS and OS or CSS
(Table 2). The LASSO regression model selected six variants for
OS in addition to age at diagnosis, sex and AJCC stage to mini-
mize prediction error in the train set. However, nearly no incre-
mental predictive improvement was observed compared to the
model without genetic variants in the test set (C-statistic for OS:
0.73282 vs. 0.73277, U-statistic test: p = 0.322). Similar results were
found for CSS (Supporting information Table S5).
We used a concept of statistical significance as decision
criteria to define if the risk variants have an effect on survival.
This concept has been criticized in the literature as subjective
and commonly misused.24,25 We additionally looked into
Table 1. Basic characteristics of included CRC cases
Characteristics SOCCS CRC cases (n = 5,675)












Colon and rectum 16 (0.3%)
Unknown 66 (1.2%)
Follow-up time (years)1 5.09 (2.43–11.42)
No. of all-cause deaths 1,918 (33.8%)
No. of CRC-related deaths 1,358 (23.9%)
1Median and quartiles in parenthesis.
Abbreviations: AJCC, American Joint Committee on Cancer; CRC, colorectal
cancer; SOCCS, Study of Colorectal Cancer in Scotland.
Figure 1. Power curve for overall and CRC-specific survival using additive model. Abbreviations: CRC, colorectal cancer; MAF, minor allele
frequency. [Color figure can be viewed at wileyonlinelibrary.com]
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direction of effects to overcome limitations of statistical signif-
icance. We hypothesized that in case of no effects, the CRC
risk variants will cause improvement or impairment of OS
and CSS in equal proportion. Ambiguous AT and CG genetic
variants were excluded and out of 124 tested variants only
52 risk variants were also associated with worse OS (propor-
tion of risk variants associated with worse OS 41%, 95%
CI = 33–51%) and 58 were associated with decrease in CSS
(proportion of risk variants associated with worse CSS 47%,
95% CI = 38–56%). Though not reaching suggested signifi-
cance level (p ≤ 0.05), these results are consistent with direc-
tions of effects observed in previous studies.3,4
None of the nominally significant genetic variants have
known detrimental clinically relevant effects on gene function
(Supporting Information Table S6). Rs3087967, which is
located 3’UTP of C11orf53, is known to be associated with
higher COLCA2 and C11orf53 expression in colon transverse
tissue for C allele.9,20 However, little is known about COLCA2
and C11orf53 functions. rs4759277, which is associated with
worse OS and located within intron region of LRP1, is likely
to affect binding of transcription factors and associated with
LRP1 gene expression in tibial artery and sun-exposed skin.20
Another variant with nominally significant effects on both OS
and CSS is rs10994860 variant. It is located 5’UTP of
APOBEC1 complementation factor (A1CF) and likely to affect
binding (regulomeDB score 2b). The same variant has been
previously associated with estimated glomerular filtration rate
(eGFR), a measure of the kidney’s filtration ability in serum.26
This is the first study capturing all currently identified
CRC risk genetic loci (n = 92) and investigating their associa-
tions with survival outcomes in a population-based study. Our
results indicate that overall genetic CRC susceptibility mea-
sured by GWAS-identified variants is not statistically signifi-
cantly associated with survival after CRC diagnosis. With
regard to each variant, our study, which had acceptable power
for HR > 1.2, found multiple variants (14 for OS and 10 for
CSS) associated with survival outcomes at p < 0.05, although
the significance fails to survive correction for multiple testing.
Similarly, previous studies identified some CRC-risk vari-
ants27,28 that might be associated with survival after CRC diag-
nosis, these findings were not immune to false-positive results
from multiple testing. A widely studied variant, rs9929218 lies
in the intron of CDH1 gene encoding E-cadherin, the loss of
function of which can cause tumor progression and metasta-
sis.29 Previous studies reported that the CRC-risk decreasing
allele (A) is statistically significantly associated with poor sur-
vival outcomes.27,28 However, in contrast, we observed a poten-
tially favorable effect (though not statistically significant after
multiple-testing correction) of the A allele on OS in our study
(i.e., the direction of CRC risk and prognosis are consistent in
our study). Smith et al. reported that the A allele is significantly
associated with poor response to chemotherapy, implying a
Table 2. Summarized results of association between variants at nominal significance (p < 0.05) and PRS with CRC survival
Genetic marker Overall survival CRC-specific survival
Variant Gene EA MAF2 HR1 (95% CI) p value Pfdr HR1 (95% CI) p value Pfdr
rs10161980 AL139383.1 G 0.40 1.08 (1.01–1.15) 0.019 0.251 1.06 (0.98–1.14) 0.160 0.832
rs10994860 A1CF T 0.17 1.11 (1.02–1.20) 0.016 0.251 1.13 (1.02–1.24) 0.018 0.603
rs11196171 TCF7L2 G 0.22 0.91 (0.83–0.98) 0.017 0.251 0.93 (0.85–1.03) 0.161 0.832
rs12143541 TTC22 G 0.15 1.13 (1.04–1.24) 0.006 0.251 1.13 (1.02–1.25) 0.023 0.603
rs16959063 FMN1 A 0.01 0.72 (0.53–0.97) 0.034 0.380 0.83 (0.59–1.16) 0.273 0.832
rs174537 MYRF T 0.34 1.08 (1.01–1.16) 0.019 0.251 1.05 (0.97–1.14) 0.218 0.832
rs2696839 Intergenic C 0.48 0.95 (0.90–1.02) 0.143 0.642 0.93 (0.86–1.00) 0.048 0.603
rs3087967 C11orf53 C 0.33 0.92 (0.86–0.99) 0.017 0.251 0.93 (0.86–1.00) 0.062 0.616
rs3217810 CCND2 T 0.14 1.13 (1.02–1.25) 0.016 0.251 1.13 (1.00–1.27) 0.044 0.603
rs3217874 CCND2 T 0.42 1.07 (1.00–1.14) 0.050 0.438 1.06 (0.98–1.14) 0.139 0.823
rs34405347 Intergenic G 0.08 0.84 (0.74–0.95) 0.007 0.251 0.85 (0.73–0.99) 0.042 0.603
rs35509282 Intergenic A 0.12 0.94 (0.86–1.04) 0.256 0.772 0.88 (0.78–0.99) 0.033 0.603
rs4759277 LRP1 A 0.38 1.07 (1.00–1.14) 0.051 0.438 1.09 (1.01–1.18) 0.028 0.603
rs6065668 Intergenic T 0.28 0.90 (0.83–0.96) 0.003 0.251 0.89 (0.82–0.97) 0.011 0.603
rs7495132 CRTC3 T 0.12 1.03 (0.93–1.13) 0.602 0.888 1.13 (1.01–1.26) 0.032 0.603
rs847208 LINC01081 A 0.37 0.93 (0.88–1.00) 0.042 0.416 0.92 (0.85–0.99) 0.027 0.603
rs9537521 AL139383.1 A 0.38 1.10 (1.02–1.17) 0.008 0.251 1.06 (0.98–1.15) 0.153 0.832
rs9929218 CDH1 A 0.28 0.93 (0.86–0.99) 0.035 0.380 0.96 (0.88–1.04) 0.294 0.836
PRS NA 1.00 (0.95–1.04) 0.864 NA 1.03 (0.97–1.08) 0.340 NA
1Hazard ratios are derived from Cox regression models adjusted for age at diagnosis, sex and AJCC stage.
2Minor allele frequency is the minor allele prevalence in SOCCS.
Abbreviations: CI, confidence interval; CRC, colorectal cancer; EA, effect alleles; HR, hazard ratio; MAF, minor allele frequency; NA, not available;
Pfdr, p values after correction for false positive rates; PRS, polygenic risk score.
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possible gene × therapy interaction for this variant.28 However,
our study is limited by data on response to chemotherapy
being unavailable so that this could not be explored further.
Notably, there has been other evidence showing that rs9929218
may modify CRC susceptibility by interacting with other fac-
tors such as height and alcohol consumption.30 Investigation
of possible gene–environment interactions should be consid-
ered in future efforts with large sample sizes to further dissect
the prognostic effect of this variant in CRC patients. Consis-
tently, when looking for overall direction of effects among
124 tested variants we noted little evidence of potentially det-
rimental effects of CRC risk on survival with only 41 and 47%
of risk variants showing association with poor (HR > 1) OS
and CSS in our study.
Previously we have shown that SOCCS study is representa-
tive of British and Scottish populations and cases from
SOCCS cluster tightly with population-based controls from
SOCCS and Generation Scotland.31,32 The allele frequencies of
studied genetic variants are in range expected for European
populations (Supporting Information Table S1). However, the
results may be not generalizable to populations of cancer
patients where substantial differences in allele frequencies
and/or treatment and disease management are anticipated.
In conclusion, our study finds that overall genetic suscepti-
bility to CRC captured by known CRC risk variants is not
statistically significantly associated with survival outcomes of
CRC. However, possible roles of each variant in CRC progres-
sion remain to be explored. Our study indicated that the heri-
table variation of patient survival may have distinct genetic
determinants from CRC susceptibility. The previous GWAS
on CRC survival with 3,494 cases identified no variants at
genome-wide significance (p < 5E−8),33 meriting future col-
laborative efforts of aggregating larger CRC cohorts to illumi-
nate genetic structure of survival outcomes for CRC patients.
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